Loading
Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed.
Jennifer Chan directs the neuroendocrine and carcinoid tumour programme at Dana-Farber Cancer Institute. She was the study chair and first author of the 2024 New England Journal of Medicine report of the Alliance CABINET trial, in which cabozantinib improved progression-free survival compared with placebo in previously treated advanced pancreatic and extra-pancreatic neuroendocrine tumours, supporting its approval in both groups.
| Title | Journal | Year |
|---|---|---|
| CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours | New England Journal of Medicine | 2025 |
Shares CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours, Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Neuroendocrine tumours and the tags neuroendocrine, trialist.
Shares Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Neuroendocrine tumours and the tags neuroendocrine, trialist.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.